Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 1

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 8
Chunk 1
---
 limitations and disadvantages. In contrast, silicon nitride has a legacy of success in the most demanding
and extreme industrial environments. As a human implant material, silicon nitride offers bone ingrowth, resistance to bacterial and viral
infection, ease of diagnostic imaging, resistance to corrosion, and superior strength and fracture resistance, all of which claims are
validated in our large and growing inventory of peer-reviewed, published literature reports. We believe that our versatile silicon nitride
manufacturing expertise positions us favorably to introduce new and innovative devices in the medical and non-medical fields.

Antipathogenic Applications:
Today, there is a global need to improve protection against pathogens in everyday life. SINTX believes that by incorporating its
unique composition of silicon nitride antipathogenic powder into products such as face masks, drapes, filters, sutures, and wound
care devices, it is possible to manufacture surfaces that inactivate pathogens, thereby limiting the spread of infection and
disease. The discovery in 2020 that SINTX silicon nitride inactivates SARS-CoV-2, the virus which causes the disease COVID-19, has
opened new markets and applications for our material. We presently manufacture advanced ceramic powders and components in our manufacturing facilities based in Salt Lake
City, Utah.

The SINTX Salt Lake City facility is registered
with the FDA, is cGMP and ANVISA RDC 665 compliant, as well as being ISO 9001:2015, ISO 13485:2016 certified, and ASD9100D certified.
The Company’s products are primarily sold in the United States.

Basis of Presentation

These unaudited condensed consolidated financial statements
have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”)
and include all assets and liabilities of the Company.

SEC rules and regulations allow the omission of certain
information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting
principles (“U.S. GAAP”) so long as the statements are not misleading. In the opinion of management, these financial statements
and accompanying notes contain all adjustments (consisting of normal recurring adjustments) necessary to present fairly the financial
position and results of operations for the periods presented herein. These condensed consolidated financial statements should be read
in conjunction with the consolidated audited financial statements and notes thereto contained in the Company’s Annual Report on
Form 10-K for the year ended